secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001104659-26-053482
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion acquired by ARCHIMED for $3.16/share plus up to $100M in milestone payments
--------------------------------------------------------------------------------

- Cash $3.16/share + 1 CVR/share; aggregate milestone payments up to $100M based on net sales.
- Milestone triggers: $40M if 2027 U.S. sales of bempedoic acid products >$350M; $60M if ENBUMYST sales >=$160M/year through 2030.
- Close expected Q3 2026; conditions include stockholder approval, HSR clearance, and non-U.S. antitrust.
- Board unanimously recommends; termination fees: $34.15M (Esperion), $68.3M (ARCHIMED).
- Financing from ARCHIMED affiliates and third-party debt; no financing condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/0001104659-26-053482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/tm2613340d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-053482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer